These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21926261)

  • 1. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
    Staszewsky L; Wong M; Masson S; Raimondi E; Gramenzi S; Proietti G; Bicego D; Emanuelli C; Pulitanò G; Taddei F; Nicolis EB; Correale E; Fabbri G; Bertocchi F; Franzosi MG; Maggioni AP; Tognoni G; Disertori M; Latini R;
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):721-8. PubMed ID: 21926261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    Disertori M; Lombardi F; Barlera S; Maggioni AP; Favero C; Franzosi MG; Lucci D; Staszewsky L; Fabbri G; Quintarelli S; Bianconi L; Latini R
    Am Heart J; 2011 Aug; 162(2):382-9. PubMed ID: 21835301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valsartan for prevention of recurrent atrial fibrillation.
    ; Disertori M; Latini R; Barlera S; Franzosi MG; Staszewsky L; Maggioni AP; Lucci D; Di Pasquale G; Tognoni G
    N Engl J Med; 2009 Apr; 360(16):1606-17. PubMed ID: 19369667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study.
    Bang CN; Dalsgaard M; Greve AM; Køber L; Gohlke-Baerwolf C; Ray S; Rossebø AB; Egstrup K; Wachtell K
    Int J Cardiol; 2013 Oct; 168(3):2322-7. PubMed ID: 23416018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of New-Onset Atrial Fibrillation in Patients Receiving CRT: Mechanistic Insights From Speckle Tracking Imaging.
    Sade LE; Atar I; Özin B; Yüce D; Müderrisoğlu H
    JACC Cardiovasc Imaging; 2016 Feb; 9(2):99-111. PubMed ID: 26684972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between left atrial phasic conduit function and early atrial fibrillation recurrence in patients undergoing electrical cardioversion.
    Degiovanni A; Boggio E; Prenna E; Sartori C; De Vecchi F; Marino PN;
    Clin Res Cardiol; 2018 Apr; 107(4):329-337. PubMed ID: 29181725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of catheter ablation in nonparoxysmal atrial fibrillation patients with severe enlarged left atrium and its impact on left atrial structural remodeling.
    Pump A; Di Biase L; Price J; Mohanty P; Bai R; Santangeli P; Mohanty S; Trivedi C; Yan RX; Horton R; Sanchez JE; Zagrodzky J; Bailey S; Gallinghouse GJ; Burkhardt JD; Natale A
    J Cardiovasc Electrophysiol; 2013 Nov; 24(11):1224-31. PubMed ID: 24020717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE; Kjeldsen SE; Julius S; McInnes GT; Zanchetti A; Hua TA;
    J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
    Disertori M; Franzosi MG; Barlera S; Cosmi F; Quintarelli S; Favero C; Cappellini G; Fabbri G; Maggioni AP; Staszewsky L; Moroni LA; Latini R;
    BMC Cardiovasc Disord; 2013 Apr; 13():28. PubMed ID: 23586654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    Disertori M; Lombardi F; Barlera S; Latini R; Maggioni AP; Zeni P; Di Pasquale G; Cosmi F; Franzosi MG;
    Am Heart J; 2010 May; 159(5):857-63. PubMed ID: 20435196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of good responders to rhythm control of paroxysmal and persistent atrial fibrillation by transthoracic and transesophageal echocardiography.
    Wang YC; Lin LC; Lin MS; Lai LP; Hwang JJ; Tseng YZ; Tseng CD; Lin JL
    Cardiology; 2005; 104(4):202-9. PubMed ID: 16155395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left atrial ejection force predicts the outcome after catheter ablation for paroxysmal atrial fibrillation.
    Kishima H; Mine T; Takahashi S; Ashida K; Ishihara M; Masuyama T
    J Cardiovasc Electrophysiol; 2018 Feb; 29(2):264-271. PubMed ID: 29125704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial asynchrony and function before and after electrical cardioversion for persistent atrial fibrillation.
    Dell'Era G; Rondano E; Franchi E; Marino PN;
    Eur J Echocardiogr; 2010 Aug; 11(7):577-83. PubMed ID: 20400765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in left atrial size in patients with persistent atrial fibrillation: a prospective echocardiographic study with a 5-year follow-up period.
    Wozakowska-Kapłon B
    Int J Cardiol; 2005 May; 101(1):47-52. PubMed ID: 15860382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
    Latini R; Masson S; Pirelli S; Barlera S; Pulitano G; Carbonieri E; Gulizia M; Vago T; Favero C; Zdunek D; Struck J; Staszewsky L; Maggioni AP; Franzosi MG; Disertori M;
    J Intern Med; 2011 Feb; 269(2):160-71. PubMed ID: 20964739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study.
    Olshansky B; Heller EN; Mitchell LB; Chandler M; Slater W; Green M; Brodsky M; Barrell P; Greene HL
    J Am Coll Cardiol; 2005 Jun; 45(12):2026-33. PubMed ID: 15963405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of atrial fibrillation ablation on left ventricular filling pressure and left atrial remodeling.
    Santos SN; Henz BD; Zanatta AR; Barreto JR; Loureiro KB; Novakoski C; Santos MV; Giuseppin FF; Oliveira EM; Leite LR
    Arq Bras Cardiol; 2014 Dec; 103(6):485-92. PubMed ID: 25590928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs.
    Li Y; Li WM; Gong YT; Li BX; Liu W; Han W; Dong D; Sheng L; Xue JY; Zhang L; Chu S; Yang BF
    Basic Res Cardiol; 2007 May; 102(3):245-56. PubMed ID: 17268887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.